Prometheus Biosciences Inc
RXDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.56B
Close$
$206.54
3.3% upside
Current Fair Value
3.3% upsideUndervalued by 3.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.56 Billion |
|---|---|
| Enterprise Value | $9.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.49 |
| Beta | -0.49 |
| Outstanding Shares | 47,461,230 |
Return
| Return on Equity | -21.38% |
|---|---|
| Return on Assets | -19.66% |
| Return on Invested Capital | -22.03% |
Valuation & Multiples
| P/E Ratio | -57.28 |
|---|---|
| PEG | -207.6 |
| Price to Sales | - |
| Price to Book Ratio | 14.28 |
| Enterprise Value to Revenue | 2371.91 |
| Enterprise Value to EBIT | -58.19 |
| Enterprise Value to Net Income | -64 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Prometheus Biosciences Inc
26 employeesPrometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis...